Our Expert R&d Team Has Over 10 Years Of Experience In Vhh Field
Who We Are
10
+
Our Expert R&d Team Has Over 10 Years Of Experience In Vhh Field
1000
+
1,000+ Sdab Pre-Discovery Projects Delivered
20
+
20+ Partnered Projects With IND Approvals
2000
+
2000+ Nanobody/VHH Products Developed
AlpVHHs® specializes in developing and producing customized, high-performance alpaca nanobodies. We provide tailored single-domain antibody (VHH or sdAb) pre-discovery CRO services and innovative nanobody products as the next-generation RUO tools for life science research.
We possess industry-leading Phage Display and Yeast Surface Display platforms, as well as two dedicated animal farms housing over 800 Camelids (including alpacas, llamas, and camels), ensuring traceable and well characterized animal sources for the development of high-quality recombinant nanobodies (VHHs). Our main VHH product series includes Nanoselector, tag-specific nanobodies, nano-secondary antibodies, recombinant nano-secondary antibodies, Smart Booster, and more. These products are widely applied in IP, IF, super resolution imaging, cell sorting, and antibody endocytosis detection.
Our expert R&D team has over 10 years of experience in VHH field. We have collaborated with more than 300 biotech and biopharma companies, as well as universities, successfully delivering over 1,000 sdAb pre-discovery projects. Additionally, more than 20 collaborative projects have successfully progressed to IND approval.
We are dedicated to simplifying and accelerating scientific research by delivering innovative, efficient, and user friendly solutions in the life sciences.
Corporate Vision
Contribute to providing innovative nanobody products as next-generation RUO tools for life science research.
Corporate values
Dedicated to advancing the VHH field development and providing innovative solutions for complex healthcare challenges.
Why Choose Us
We possess industry-leading Phage Display and Yeast Surface Display platforms, as well as two dedicated animal farms housing over 800 Camelids (including alpacas, llamas, and camels), ensuring traceable and well characterized animal sources for the development of high-quality recombinant nanobodies (VHHs).
Leading VHH R&D platforms
Comprehensive Immunization Platform
Top Yeast Surface Display Platform
Advanced Phage Display Platform
Outstanding R&D Capability
Independently developed next-generation nanobody conjugates for antibody internalization detection and ADC detection tools, outperforming traditional reagents in stability, miniaturization, and signal-to-noise ratio, suitable for high-throughput applications.
Comprehensive Product System
Offers multiple categories including recombinant secondary antibodies, tag antibodies, flow cytometry antibodies, etc., all of which are produced by recombinant expression to meet the diverse needs of scientific research and pharmaceutical companies.
Precise and Efficient Services
With quality as the core, provide standardized and professional technical services, commit to becoming your partner in VHHbased therapy development.
QC
Step
01
IQC
Incoming Quality Control
Step
02
IPQC
In-Process Quality Control
Step
03
FQC
Final Quality Control
Step
04
OQC
Outgoing Quality Control
Step
05
QMS
Quality Management System
Bo Chen
Founder And CEO Of AlpVHHs
Our Team
Focusing on innovative research in the field of nanobodies for more than 10 years. He has profound expertise and rich practical experience in phage display, yeast surface display technology and antibody engineering, and has a number of authorized invention patents, which cover the discovery, design and application of nanobodies and other key areas. Many research results have been published in top international academic journals such as Nature Communications, Frontiers in Immunology and Molecular Pharmaceutics, and are highly recognized by academia and industry.
Under the leadership of Mr. Bo Chen, AlpVHHs has grown into a leader in the field of nanobody research, established a world-class high-throughput nanobody research platform, and cooperated with more than 200 pharmaceutical companies at home and abroad to promote a variety of drugs into the clinical trial stage, making important contributions to the development of new drugs and innovative therapies for disease treatment.
Dr. Bo Chen
Founder And CEO Of AlpVHHs
Our Team
Focusing on innovative research in the field of nanobodies for more than 10 years. He has profound expertise and rich practical experience in phage display, yeast surface display technology and antibody engineering, and has a number of authorized invention patents, which cover the discovery, design and application of nanobodies and other key areas. Many research results have been published in top international academic journals such as Nature Communications, Frontiers in Immunology and Molecular Pharmaceutics, and are highly recognized by academia and industry.
Under the leadership of Mr. Bo Chen, AlpVHHs has grown into a leader in the field of nanobody research, established a world-class high-throughput nanobody research platform, and cooperated with more than 200 pharmaceutical companies at home and abroad to promote a variety of drugs into the clinical trial stage, making important contributions to the development of new drugs and innovative therapies for disease treatment.
Certificate
ISO9001
Humanized single-domain antibody targeting Claudin 18.2
Method for detecting antibody internalization and use of nanobody-toxin drug conjugate thereof
Anti human chorionic gonadotropin beta subunit nanobody and nucleic acid molecule and use thereof
Anti-staphylococcal protein A subunit B nanobody and nucleic acid molecule and use thereof
Anti-hepatitis B surface antigen nanobody and nucleic acid molecule and use thereof
Anti-urease subunit B nanobody and nucleic acid molecule and use thereof
Academic Partners
Industrial Partners
